Primary Care Screening for Nonalcoholic Fatty Liver Disease Among People With HIV in the United States: A Real-World Provider Survey
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in people with HIV (PWH) and increases the risk of hepatic fibrosis and hepatocellular carcinoma. We sent an online survey to providers of the American Academy of HIV Medicine. Of respondents ( n = 214, 8% response rate), 65% reported screening for NAFLD in PWH, with 28% routinely screening all patients. Most respondents refer patients to hepatology if workup suggests another coexisting liver disease or cirrhosis, with the primary goals of referral being additional diagnostic testing (60%) or specific treatments (75%). The most common barriers to screening were feeling unsure of what tests to order (28%) and how to conclusively diagnose NAFLD (29%). Most respondents were interested in society guidelines (73%) and NAFLD education for patients (57%) and providers (55%). Our findings support the development of NAFLD clinical practice guidelines for HIV providers and the inclusion of PWH in clinical trials of novel agents.
Authors
- Sonya L. Heath (ORCID: https://orcid.org/0000-0002-3826-0954)
- Susanna Naggie (ORCID: https://orcid.org/0000-0001-7721-6975)
- Rohit Seth Loomba (ORCID: https://orcid.org/0000-0002-4845-9991)
- Mark Sulkowski (ORCID: https://orcid.org/0000-0002-2145-6352)
- Jordan E. Lake (ORCID: https://orcid.org/0000-0002-0640-5514)
- Kyoko Hirose
- Jennifer C. Price (ORCID: https://orcid.org/0000-0002-3825-5696)
- Laura Wilson (ORCID: https://orcid.org/0000-0002-6294-4504)
- Holly Crandall
- Richard K. Sterling (ORCID: https://orcid.org/0000-0002-8637-2475)
- Naga Chalasani (ORCID: https://orcid.org/0000-0003-2359-6030)
Institutions
- University of California, San Francisco (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Journal of the Association of Nurses in AIDS Care
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1097/jnc.0000000000000505
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Arrowhead Pharmaceuticals
- NGM Biopharmaceuticals
- Novo Nordisk
- Genentech
- National Institute of Diabetes and Digestive and Kidney Diseases